These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 9019118)
21. [Effect of Acrinor on various functions of the cardiovascular system and lungs]. Jedlicka K; Krofta K; Nikodýmová L Cas Lek Cesk; 1973 Jan; 112(3):80-3. PubMed ID: 4405272 [No Abstract] [Full Text] [Related]
22. Stimulants and sudden death: what is the real risk? Furman L Pediatrics; 2007 Feb; 119(2):409; author reply 409-10. PubMed ID: 17272634 [No Abstract] [Full Text] [Related]
24. [Conference on "current attituder towards doping"]. ADM; 1968; 25(6):473-7. PubMed ID: 4387434 [No Abstract] [Full Text] [Related]
25. Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion. Bell DG; Jacobs I; McLellan TM; Miyazaki M; Sabiston CM Aviat Space Environ Med; 1999 Jun; 70(6):583-8. PubMed ID: 10373050 [TBL] [Abstract][Full Text] [Related]
27. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666 [TBL] [Abstract][Full Text] [Related]
28. Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe. Griffiths P; Mravcik V; Lopez D; Klempova D Drug Alcohol Rev; 2008 May; 27(3):236-42. PubMed ID: 18368604 [TBL] [Abstract][Full Text] [Related]
29. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Hallas J; Bjerrum L; Støvring H; Andersen M Am J Epidemiol; 2008 Oct; 168(8):966-73. PubMed ID: 18756018 [TBL] [Abstract][Full Text] [Related]
31. [Medication for ADHD and the risk of cardiovascular mortality]. Langendijk PN; Wilde AA Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941 [TBL] [Abstract][Full Text] [Related]
32. [Medication for ADHD and the risk of cardiovascular mortality]. Kalverdijk LJ; Buitelaar JK; van der Gaag RJ Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2283-4; author reply 2284. PubMed ID: 17078147 [No Abstract] [Full Text] [Related]
33. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Borum ML Am J Gastroenterol; 2001 May; 96(5):1654-5. PubMed ID: 11374728 [No Abstract] [Full Text] [Related]
34. Hidden amphetamines: from smoking cessation to diabetes. Prescrire Int; 2004 Feb; 13(69):18-20. PubMed ID: 15055218 [TBL] [Abstract][Full Text] [Related]
35. [Malnutrition in children with DAMP?]. Andersen LL Ugeskr Laeger; 2009 Mar; 171(10):824. PubMed ID: 19280776 [No Abstract] [Full Text] [Related]
36. Cardiovascular toxicity after ingestion of "herbal ecstacy". Zahn KA; Li RL; Purssell RA J Emerg Med; 1999; 17(2):289-91. PubMed ID: 10195489 [TBL] [Abstract][Full Text] [Related]
37. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Knight M Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281 [No Abstract] [Full Text] [Related]
38. ECGs before stimulants in children. Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112 [No Abstract] [Full Text] [Related]
39. Inconclusive evidence puts Adderall back on the market. Kondro W CMAJ; 2005 Oct; 173(8):858. PubMed ID: 16217102 [No Abstract] [Full Text] [Related]
40. Restricting the sale of pseudoephedrine to prevent methamphetamine production. Colker AC NCSL Legisbrief; 2005 Feb; 13(7):1-2. PubMed ID: 15726724 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]